Study Phase 3

An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment86% Female14.3%% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-USA-305Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)35

Supporting Documentation

  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the synoptic report is available.

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.